GIGABYTE
14.4.2020 11:02:06 CEST | Business Wire | Press release
The leading personal computer brand, GIGABYTE, recently received the 2020 Red Dot Design Award for two creator laptops from the AERO line – AERO 15 OLED & AERO 17 – as well as two professional gaming laptops – AORUS 15G and AORUS 17X. The recognition further establishes GIGABYTE’s role as a market leader in the laptop industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200414005017/en/
There were over 6,500 entries from 60 countries contending in this year’s Red Dot Design Awards. GIGABYTE is committed to producing the AERO Creator Laptop and AORUS Gaming Laptop lines in Taiwan. With their ultra-slim bezel, Xrite Pantone color calibration, Microsoft Azure AI, and other industry leading technologies, GIGABYTE’s laptops have already been recognised with the European Hardware Awards for Best Notebook as well as receiving Taiwan Excellence Awards. The notebooks are now honored with the 2020 Red Dot Design Award.
AORUS: Redefining Gaming Laptops
AORUS laptops are fast and powerful, with screens that offer a high refresh rate coupled with exceptional mechanical keyboards. In 2020, AORUS takes it further by collaborating with G2 Esports, a professional global esports team, to develop a purpose-built gaming laptop that caters to professional gamer’s needs. The comprehensive and integrative design concept was crucial for GIGABYTE in winning the award.
The product design is infused with a sense of extreme performance, with the flagship AORUS 17X being inspired by super cars and a fighter jet. The chassis is created using CNC (Computer Numerical Control) technology, carving the all-aluminum chassis into a robust frame with defined angles. RGB LED lights are scattered from end to end showcasing the flagship laptop’s overwhelming speed and power.
The second winning laptop, the brand new AORUS 15G, is a professional gaming laptop for on-the-road gamers: though also equipped with a mechanical keyboard, the AORUS 15G is lighter and has a longer lasting battery. The design of AORUS 15G was also inspired by sports cars with the side of the chassis embellished with faux race car features to create a feel of extreme sports while adding a touch of minimalist modernism.
AERO: An Equilibrium of Performance and Mobility
The aesthetic of the creator laptops in the AERO line are inspired by science fiction films. The full aluminum chassis is finished with NIL (Nano-Imprint Lithography), presenting superior quality that is simple but by no means underwhelming. Steven Chen, VP of GIGABYTE’s Mobile Business Center, stated that the beauty of AERO laptops lies in “more possibilities” and therefore they must have lighter bodies, long-lasting batteries, and great performance without any compromise due to overheating.
The AERO line is well-balanced in many aspects, visual artist Rus Khasonov was inspired by AERO to create videos with the AERO 15 OLED, “With AERO, I can render with After Effects and edit with Photoshop at the same time. I’m deeply impressed that such a light body can offer such performance.”
The full line of creator laptops from AERO, including the 15” AERO 15 OLED and 17” AERO 17 HDR with 4K monitors as well as the AERO 15 and AERO 17 with FHD monitors, are available starting on 16th April. The graphics card powerhouse, NVIDIA, is upping the prize for creators and has promised free access to Adobe Creative Cloud for three months to anyone buying the RTX Studio equipped models. For details, please refer to the official website: https://www.gigabyte.com/Laptop
- ENDS -
About GIGABYTE
GIGABYTE is an engineer, visionary, and leader in the world of tech that uses its hardware expertise, patented innovations, and industry leadership to create, inspire and advance. Renowned for over 30 years of award-winning excellence, GIGABYTE is a cornerstone in the HPC community, providing businesses with server and data center expertise to accelerate their success. At the forefront of evolving technology, GIGABYTE is devoted to inventing smart solutions that enable digitalization from edge to cloud, and allow customers to capture, analyze, and transform digital information into economic data that can benefit humanity and "Upgrade Your Life". Please visit https://www.gigabyte.com/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom